Drugs / Glesatinib
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01930006 | Aug → Dec 2013 | cancer | Mirati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00975767 | Aug 2009 → Jul 2013 | non-small cell lung carcinoma | Mirati Therapeutics Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00697632 | Jun 2008 → Sep 2018 | — | Mirati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00679133 | Apr 2008 → Mar 2011 | cancer | Mirati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT02954991 | Nov 2016 → Nov 2021 | non-small cell lung carcinoma | Mirati Therapeutics Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02544633 | Oct 2015 → Apr 2018 | non-small cell lung carcinoma | Mirati Therapeutics Inc. | Completed | Missed primary |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Glesatinib | “Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel” PMID 35347559 ↗ Mar 20223“Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in” PMID 36459255 ↗ Dec 2022 “Glesatinib (MGCD265) is an investigational, oral inhibitor of MET and AXL.” PMID 38417277 ↗ Feb 2024 |
| Known as | MG-90265 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989914 ↗ |
| Known as | MG-90265X | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989914 ↗ |
| Known as | MG90265gly | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989914 ↗ |
| Known as | MG90265H9 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989914 ↗ |
| Known as | MGCD265 | “Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel” PMID 35347559 ↗ Mar 20224“Glesatinib (MGCD265) is an investigational, oral inhibitor of MET and AXL.” PMID 38417277 ↗ Feb 2024 |
| Action | Inhibit | “Macrophage-stimulating protein receptor inhibitor” CHEMBL3989914 ↗2“inhibits MET and AXL at clinically relevant doses” PMID 35347559 ↗ Mar 2022 “Tyrosine-protein kinase TIE-2 inhibitor” CHEMBL3989914 ↗ |
| Modality | Small molecule | “MGCD265 is a small molecule multi-targeted receptor tyrosine kinase inhibitor” NCT02544633 ↗ |
| Route | Oral | “Oral daily administration; 7 days on / 7 days off” NCT00679133 ↗ |
| Target | AXL | “inhibits MET and AXL at clinically relevant doses” PMID 35347559 ↗ Mar 2022 |
| Target | MET | “inhibits MET and AXL at clinically relevant doses” PMID 35347559 ↗ Mar 2022 |
| Target | MST1R | “Macrophage-stimulating protein receptor inhibitor” CHEMBL3989914 ↗ |
| Target | TEK | “Tyrosine-protein kinase TIE-2 inhibitor” CHEMBL3989914 ↗ |